Article info

Download PDFPDF

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Authors

  1. q 646-638-5008 Driscoll_kyla{at}lilly.com
View Full Text

Citation

Holmgaard RB, Schaer DA, Li Y, et al
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Publication history

  • Received February 13, 2018
  • Accepted May 11, 2018
  • First published June 4, 2018.
Online issue publication 
June 04, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.